With the growing awareness and concern regarding estrogens in the environment, the selection of reliable and appropriate methods for their detection and characterization has taken on considerable importance. The relevant literature covering the period from 1920 to 1996 was surveyed to identify methods that have been used to assay estrogens in mammalian systems. The estrogen biological assays identified were grouped into four categories: (1) reproductive tract response; (2) non-reproductive-tract target tissue response; (3) estrogen receptor binding; and (4) estrogen receptordependent transcriptional expression. The biological assays were summarized and their advantages and disadvantages discussed. A possible testing scheme also was provided to characterize estrogens, anti-estrogens, and pro-estrogens (chemicals metabolically Converted tO estrogens). © 1996 Society of Toxicology.
Considerable scientific and popular press attention has been devoted to the question of whether synthetic or natural chemicals affect the endocrine system at the levels at which they are found in the environment. Synthetic chemicals, such as the drug diethylstilbestrol (DES) and the insecticide dichlorodiphenyltrichloroethane (DDT), mimic many of the biological activities of the natural steroidal estrogen estradiol-17/3 (E 2 ). That mimicry of E 2 and the knowledge that such compounds can cause adverse effects on reproduction and the endocrine system have raised concerns about environmental estrogens (McLachlan, 1993) . DES was designed to have potent estrogenic activity after oral administration. It was administered clinically to pregnant women at pharmacologically active doses, and many of their offspring developed reproductive defects due to what turned out to be an inappropriate estrogen exposure to the developing reproductive system. DDT is an organochlorine insecticide that the U.S. government banned because it caused eggshell thinning in birds, presumably by acting via estrogenic mechanisms. The adverse effects associated with these two chemicals led to attention being focused on the potential of environmental agents to act as estrogens in vivo. Throughout this survey, "estrogen" is used as a generic term, whereas specific estrogenic hormones or chemicals are referred to by their common names.
Hypotheses have been developed, although supported to varying degrees, that environmental estrogens may be responsible for increases in breast cancer (Wolff et ai, 1993; Toniolo etai, 1995; Davis, 1993) , decreases in avian fertility (Colborn, 1993) , decreases in male fertility (Sharpe and Skakkebaek, 1993; Auger etai, 1995) , and altered reproductive tissues in male alligators (Guilette et al., 1994) . Many of the effects that have been reported are contested as to whether they are real and whether estrogens or anti-estrogens have anything to do with them (Sherins, 1995; Safe, 1994; Krieger et al, 1994; McMahon, 1994) . One point that is repeatedly made by all parties interested in these issues is that additional work is required on the hypothesis that xenoestrogens (naturally occurring phyto-and fungal estrogens and man-made estrogenic chemicals), also referred to as environmental estrogens, are present in the environment at levels that are biologically meaningful.
Synthetic and natural chemicals may theoretically modulate the endocrine system as either hormonal mimics or hormonal blockers or both (McLachlan, 1993) . While a variety of molecular mechanisms is possible (Chapin et al, 1996) , the pertinent mechanism for this discussion is that endocrine modulators could act through hormone receptors and enhance or diminish the activity normally controlled by endogenous hormones. Assay systems could be useful to determine whether or not a chemical has hormone modulating activity and at what exposure levels such activities would cause effects in the environment.
One important issue is that various investigators use different endpoints to define an estrogen. In the examples given in this paper, some investigators are calling chemicals that increase cell division of the MCF-7 cell line estrogens, while others are relying on binding to estrogen receptors, and still others require growth of the rat uterus. As described in this review, each endpoint may respond independently. In any of the assays for estrogenic activity, the definition of estrogen or what constitutes a positive response will have to be stated explicitly.
This review describes selected types of mammalian biological assays that have been used to measure estrogenic activity for various agents. We have not attempted to include all estrogenic endpoints or responses. Rather, we have only included endpoints that yield dose-response relationships and that have been successfully used in bioassays. Confusion has developed in this area, in part because the term estrogen has expanded beyond the original concept that an estrogen is an agent that induces estrus. The term has been extended to include other properties. Both whole animal bioassays and in vitro biological assays have been considered. Many assays are available that indirectly relate to estrogenicity or to other types of hormonal activity, but we have chosen not to include them in this survey for sake of brevity. In addition, we have summarized our thinking by proposing a combination of selected mammalian test systems to aid in the screening and assessment of estrogenic, anti-estrogenic, and proestrogenic activity. As discussed below, we believe this combination of tests is likely to be useful for screening for the estrogenic modulation potential of chemicals.
ESTROGEN BIOLOGICAL ASSAYS

Reproductive Tract Responses
Vaginal cornification (Allen-Doisy assay) . During the 4-or 5-day estrous cycle of the rat and mouse, the vaginal epithelium undergoes characteristic estrogen-dependent changes. These changes include epithelial cell division and differentiation from cubiodal to pseudoudestratified columnar to stratified squamous keratinized cell layers, which provide a definite succession of cell types, each one characteristic of a certain stage of the estrous cycle (Bennett and Vickery, 1970) . In addition, alternating patterns of keratinization and mucification occur during the follicular (estrogenic) and luteal (progestational) phases of the estrous cycle, respectively.
Microscopic examination of vaginal smears provides a reliable method for assessing the stage of the estrous cycle. Because these cyclic changes cease after bilateral ovariectomy, the induction of vaginal keratinization and cornification by a chemical constitute useful endpoints for identifying estrogenic activity. Cornification is the conversion of proliferating columnar cells to the squamous cell type with the formation of horny cell (keratinized) layers at the vaginal luminal surface. Kertatinization is an integral part of the cornification process and refers to the epithelial cell production of keratin with the resultant formation of a keratinous (cornified) cell layer. Allen and Doisy (1923) first used the vaginal cornification response to detect estrogens in the liquor folliculi from hog ovaries. In the Allen-Doisy bioassay, young adult rats or mice are bilaterally ovariectomized and vaginal smears are examined daily for 1 or 2 weeks thereafter to ensure complete ovariectomy. Only animals exhibiting castrate smears (predominance of leukocytes with few vaginal epithelial cells) are used for the bioassay. The animals are then treated for 3 days and the smears are evaluated for several days beginning 1 day after the initial treatment. Vaginal cornification is scored qualitatively as positive (+) or negative (-). Kahnt and Doisy (1928) adopted the view that a vaginal smear with a predominance of cornified cells with some nucleated epithelial cells and very few leukocytes should be scored as a positive response. Biggers and Claringbold (1954) further demonstrated that proestrous smears (predominance of nucleated epithelial cells) should be classified as positive and also showed that the presence or the absence of leukocytes was the best criterion for classification. In the latter instance, the absence of leukocytes was judged a positive response and the presence of leukocytes a negative response. Vaginal cornification usually occurs 48 to 72 hr after administration of 17/3-estradiol. The onset and duration of cornification are directly related to the dosing schedule and the pharmacokinetics of the estrogen administered. Alternately, keratinization can be evaluated by excising and fixing the vagina, followed by sectioning, staining, and microscopic examination of the epithelium (Jones and Edgren, 1973) .
Generally, test compounds have been administered subcutaneously (sc) or orally (po). However, estrogens also have been shown to be active locally when given per vaginam (Robson and Adler, 1940; Emmens, 1942) . Curiously, the slopes of the dose-response lines obtained by the intravaginal route were significantly flatter than those obtained by sc administration (Emmens, 1950a,b; Biggers, 1951) . The flatter slope of the dose-response curve with the intravaginal route indicated wide variability in the threshold doses of estrogen required to produce vaginal cornification by this route of administration, whereas sc administration yielded steeper dose-response slopes and lower variability in the estrogen threshold doses. These observations led Biggers (1951) to conclude that the intravaginal route was not a practical mode of administration for routine vaginal cornification bioassays. Nonetheless, test compounds have been given intravaginally to determine local estrogenic activity (Robson and Adler, 1940; Emmens, 1942; Biggers and Claringbold, 1954) .
As emphasized by Jones and Edgren (1973) and Edgren (1994) , vaginal keratinization and cornification are among the most specific in vivo endpoints available for determining the estrogenic character of a compound. Other steroid hormone classes, such as androgens and progestins, stimulate vaginal mucification but do not induce epithelial keratiniza-tion or cornification (Jones and Edgren, 1973) . It also is noteworthy that ovariectomized rats and mice can be maintained and used repeatedly for vaginal smear assays provided that an adequate "wash out" period is allowed between assays (Edgen, 1994). For example, ovariectomized animals may be employed as often as every second week, depending on the duration of action of the estrogens tested. However, animals should not be used more than one time for xenobiotics that persist or are stored in the body. Conversely, ovariectomized rodents not used for assays at frequent intervals should be primed with a standard dose of estrogen to maintain estrogen sensitivity. Only animals responding to the standard estrogen dose should be used for subsequent bioassays (Edgren, 1994) .
Vaginal epithelial cell proliferation and tetrazolium reduction. The unstimulated rat vaginal epithelium of the adult ovariectomized rat consists of two or three layers of cuboidal cells with a large nuclear to cytoplasmic ratio. Twelve hours after a single sc injection of E 2 the vaginal epithelium increases slightly in height, particularly at the basal layer, but there is no increase in cell number. Within 24 hr of E 2 injection, keratin synthesis is induced and the vaginal epithelium increases to six to eight cell layers in thickness and possesses a distinctive luminal layer composed of an irregular array of vacuolated cells. Repeated administration of E 2 at 24 hr causes continued keratin synthesis, growth, and maturation, and by 48 hr the vaginal epithelium is maximally keratinized (Kronenberg and Clark, 1985) . Martin and Claringbold (1958) developed an intravaginal assay using the increase in vaginal mitosis and epithelial thickness as measures of the estrogenic response. In this assay ovariectomized adult albino mice were used. Two weeks before use, the ovariectomized mice were primed with 1 mg estrone (E,) sc in peanut oil. Estrogens were given as an aqueous suspension by one intravaginal instillation in 0.01 ml distilled water 24 hr before euthanization. Seven hours before each animal was killed, 0.1 mg colchicine in 0.05 ml distilled water was injected sc in order to arrest mitosis. Twenty-four hours after estrogen administration the vagina was excised, fixed, and processed for histological examination. The total number of arrested mitoses (cell division inhibited at metaphase) were counted in five fields for each animal, the final score being the sum of the five counts. The maximum response was elicited by 8 X 10" 5 mg E,, and the response was linearly related to log dose in the range of 0.5 X 10" 5 to 8 X 10" 5 mg E,. E 2 was 1.68 times more potent than E, in this bioassay (Martin and Claringbold, 1958) .
In comparison, Biggers (1951) found that E2 had a potency 1.75 times that of E, using an intravaginal cornification assay. It was later claimed by others that the mitotic index endpoint was 10 times as sensitive and 4 times as precise as the cornification endpoint (Martin and Claringbold, 1958) . The reason for this difference is not clear at present. In addition, the mitotic index assay was of shorter duration than the cornification assay. Conversely, the former assay required excision of the vagina and histological preparation and examination, whereas the latter assay required only microscopic readings of vaginal smears. The mitotic index assay also required more labor and technical skill than the cornification assay. Finally, the mitotic index assay necessitated the killing of the test animals, whereas in the cornification assay the animals could be used repeatedly (Edgren, 1994) . Martin and Claringbold (1960) also investigated the specificity of estrogens on mitotic activity in the vaginal epithelium of the ovariectomized mouse. In these tests three dose levels of E, were administered together with various dose levels of testosterone, progesterone, cortisol, or cortisone acetate as single intravaginal instillations in distilled water. None of these four steroid hormones altered the E| doseresponse lines for mitosis or epithelial thickness, even though the highest doses of testosterone and progesterone were 5000 times, and those of cortisol and cortisone acetate 2000 times, those of the ED50 dose of E,.
In another series of tests, 1 mg each of testosterone, progesterone, and cortisol was injected sc in peanut oil or intravaginally as a thick suspension in distilled water, and E, at 12.5 or 100 pg was given concurrently as a single intravaginal instillation in distilled water. None of the three steroid hormones inhibited E r induced mitosis or epithelial thickness. However, in combination with the lower dose of E,, testosterone enhanced mitogenic activity by both routes, while cortisol and to a lesser extent progesterone were additive with E, by the local route. Hence, other classes of hormones can modify the vaginal epithelial mitogenic response to E,. Martin (1960) stated that estrogens stimulate reductase enzymes in the vaginal epithelium and further demonstrated that the reduction of 2,3,5-triphenyltetrazolium chloride to formazan in the vaginal epithelium following local application of estrogens could form the basis of a sensitive assay. 2,3,5-Triphenyltetrazolium chloride is a pale yellow, nontoxic, water-soluble compound that is a substrate for reductase activity in vaginal epithelial cells. Estrogen stimulates reductase activity which acts on the substrate to form a stable, water-insoluble, deep red pigment that is precipitated at the site of reaction. The reduction product, formazan, is soluble in various organic solvents and can be extracted directly from vaginal tissues (without homogenization) and estimated colorimetrically (Martin, 1960) . In the tetrazolium reduction assay, E 2 was 1.4 and diethylstilbestrol (DES) was 2.8 times as potent as E, following intravaginal administration to ovariectomized adult mice. Testosterone, progester-one, and cortisol did not increase tetrazolium reduction at doses 1000 times that of E H indicating the specificity of this endpoint (Martin, 1960) . It is noteworthy that enhanced reduction of tetrazolium by the vaginal epithelium 24 hr after administration of estrogens parallels cell growth in most respects and may be considered an index of cell growth. The tetrazolium reduction assay also is comparable in sensitivity and accuracy to assays involving mitosis and epithelial thickness, with the added advantage of simplicity (Martin, 1960) . However, this assay has the disadvantage that the animals must be killed and the vagina excised.
Vaginal opening. The vagina of the immature rat is completely closed, its external one-third being a solid cord of cells (Allen and Doisy, 1924) . The opening of the vaginal orifice and the appearance of the first signs of estrus in these animals may be used as one definition of sexual maturity (Allen and Doisy, 1924) . It also is important to point out that the first ovulation usually occurs about 5 days after the opening of the vagina (Allen and Doisy, 1924) . Precocious vaginal opening may be induced by the administration of various estrogens, but this endpoint has not been employed frequently for quantitative assays (Emmens, 1962) . Edgren et al. (1966) noted that 50% of the vaginae of Charles River rats (strain not given) were open by the 40th day of life. These workers further noted that the dose of estrogen required to produce 100% vaginal opening by Day 30 was a satisfactory criterion for assessing estrogenic activity. In order to compare the effects of E 2 and 18-homoestradiol (18-methylestra-l,3,5(10)-triene-3, 17/3-diol) on vaginal opening, sc injections of graded doses were begun on Day 25 and continued until Day 42 of age. It was found that daily doses of 0.03 mg E 2 /rat were effective in causing vaginal opening on Day 30 in 100% of the treated rats, whereas 0.3 mg 18-homoestradiol/rat was required to achieve this same effect. Thus, the 18-homologated form of E 2 was only 10% as potent as E 2 in this assay (Edgren et al., 1966) . Lerner (1964) found that the nonsteroidal estrogen antagonist ethamoxytriphetol (MER-25) was estrogenic as measured by precocious vaginal opening. Although MER-25 is classified as an estrogen antagonist, it also acts as a partial agonist (estrogen) in the rat uterotrophic bioassay (Lerner, 1964) . Thus, in weanling rats exposed at 5 mg MER-25/kg feed, vaginal opening occurred in 100% of the rats by Day 39 of age, whereas in controls 100% opening did not occur until Day 50. In addition, when 5 mg MER-25 was injected daily sc into pregnant rats from Gestation Days 16 through 22, vaginal opening occurred in 100% of the female offspring by Day 42 of age compared to Day 51 for the control offspring (Lerner, 1964) .
Other nonsteroidal estrogen antagonists (MRL-41 and U 11,555A) with partial agonist activity also have been found to cause premature vaginal opening in immature rats (Coppola and Perrine, 1965) . Vaginal opening does not, however, always respond in parallel to other endpoints. For example, in another study (Eroschenko and Cook, 1990) , daily intraperitoneal (ip) injection of neonatal mice from the day of birth to Day 10 with 0.5 or 1.0 mg methoxychlor induced precocious vaginal opening, vaginal cornification, and reproductive tract weight increase as measured on Day 10. The reproductive tract included the ovaries, oviducts, uterus, vagina, and external genitalia. A lower daily dose of 0.1 mg methoxychlor also increased reproductive tract weight, but did not induce vaginal opening or cornification. Thus, the increase in reproductive tract weight appeared to be a more sensitive estrogenic endpoint than did vaginal opening or cornification for this compound.
Vaginotrophic response. The increase in vaginal wet weight in response to estrogens has been little used as a quantitative endpoint. This may be due to the fact that it is usually more convenient to excise either the uterus or the entire reproductive tract than the vagina for weighing. Using the growth of the vagina and uterus of the immature mouse, Folman and Pope (1966) investigated the interaction of the partial agonists/antagonists, coumestrol, genistein, dimethylstilbestrol (DMS), norethindrone acetate, and megestrol acetate, with the potent estrogens, E 2 , E lt and DES. Sc injections were given at 0900 and 1700 hours on 3 consecutive days, and the mice were euthanized at 70 to 74 hr after the initial injection. While the vaginal weight of control mice (13 mg) was on average 43% greater than the control uterine weight (9 mg), the maximum weight obtained for either organ with estrogenic stimulation was 45 mg. For total doses of E, of 0.025, 0.05, and 0.1 mg, increments of uterine growth over controls were 68, 109, and 249% and of vaginal growth, 78, 158, and 262%. DES and E 2 gave similar results. Finally, nonsteroidal estrogen antagonists exhibited similar antagonistic potencies in the uterus and vagina. Thus, although the organ weight responses are comparable for the vagina and uterus, the uterotrophic response will probably remain the endpoint of choice since it is easier to excise and weigh the uterus than it is the vagina.
Uterine fluid imbibition (Astwood bioassay).
During the first few hours following a systemic injection of an estrogen, the uterus of the immature rat shows an increase in weight due almost entirely to an accumulation of water followed by a weight gain representing tissue growth. Based on the quantitative aspects of the first phase of this biphasic response, Astwood (1938) devised a simple and accurate estrogen bioassay.
To determine the time course of the water imbibition response groups of immature female rats (21 to 23 days of age) were injected sc with 0.1 mg E 2 and killed at intervals thereafter. Uterine wet weights, water content, and uterine dry weights were obtained and histological sections pre-pared. During the first hour no effect was seen, but by the second hour a slight but definite increase in uterine wet weight had occurred. Thereafter, uterine wet weight increased rapidly, reaching a maximum at 6 hr. By 12 hr onefourth of the weight previously gained was lost, but during the next 18 hr there was a second increase in weight that was maximal by 30 hr. The uterus then returned toward a basal state.
During the early stages of the estrogen response, the uteri were swollen, edematous, and translucent, with vascularity somewhat increased. Water determinations (uterine wet weight minus versus uterine dry weight) confirmed that the early increase in weight was almost entirely due to an increased water content and that the fall at 12 hr was due to water loss. Moreover, the second weight increase was not accompanied by water uptake, but rather represented a true tissue growth response (Astwood, 1938) . Historically, the Astwood assay involves the measurement of uterine weight during the first 4 to 6 hr after estrogen treatment during the fluid imbibition phase. Astwood (1938) further showed that a direct proportionality existed between uterine wet weight at 6 hr and the dose of E 2 . The initial assays were conducted by determining the minimal quantity of E 2 that would give a maximal uterine weight increase at 6 hr. Although this initial method worked well, it had the disadvantage of being a quantal response, giving no information regarding graded doses of estrogen. Astwood (1938) therefore decided to develop a more definitive bioassay. The standard dose-response curve obtained gave a direct relationship between logarithmic doses of E 2 (ranging from 0.006 to 0.1 mg per rat) and uterine weight. Using the 6-hr fluid imbibition assay, Astwood (1938) found E 2 to be 12 times more potent than E,. Hisaw (1959) compared five natural estrogens [E 2 , E,, estriol (E 3 ), equilin, and equilenin] and DES as to their effectiveness in promoting fluid imbibition and growth of the uterus in 22-day-old rats. Graded quantities of each estrogen were injected sc as a single dose in 0.1 ml sesame oil and uterine responses observed at intervals up to 72 hr. Both quantitative and qualitative differences were found with respect to the dose required for a response and onset, duration, and extent of response. Some estrogens were more potent for fluid imbibition and others more potent for tissue growth. The minimal dose in milligrams required to produce a 33% increase in uterine wet weight at 6 hr (Astwood unit) was for E 2 , 0.025; E 3 , 0.029; DES, 0.078; equilin, 0.312; E,, 0.45; and equilenin, 0.546. However, the milligram dose required to produce a 70% gain in uterine wet weight at 6 hr shows a different ranking of potency: E 3 , 0.078; E 2 , 0.1; DES, 0.156; equilenin, 0.625; E,, 1.25; and equilin, 1.25. It was further noted that for high doses, uterine wet weights obtained at 4 hr for high doses were greater than those at 6 hr for the same dose.
Thus, as the dosage of an estrogen was increased the time of maximal fluid imbibition occurred earlier than that obtained with smaller doses. These observations indicated that in order to evaluate the fluid imbibition response adequately it might be necessary to compare dose-response curves at both 4 and 6 hr.
Both low and high doses of estrogens were employed for comparisons of the growth responses (uterine dry weight) following a single injection (Hisaw, 1959) . The order of potency for uterine growth between the 30th and 40th hour by the milligram dose required for maximal fluid imbibition at 6 hr (low dose) was found to be DES, 0.1; E 2 , 0.1; equilin, 1.25; E 3 , 5.0; E,, 1.25; and equilenin, 1.25. In contrast, the order of effectiveness for growth at the single high dose (50 mg) was DES, E 2 , equilin, E,, equilenin, and E 3 . These studies show that while the actions of different estrogens are similar, each has its own individual potency for a given endpoint, as well as different character and extent of response (Hisaw, 1959) . The 6-hr fluid imbibition assay has the disadvantage of not distinguishing between full or longacting estrogens and partial or short-acting agonists and also has the drawback that the time course of the response is influenced by differences in the release of test compounds from the injection site. (Jordan et al., 1985) .
Uterotrophic response. The increase in uterine weight in response to an estrogenic stimulation has been used by many workers to assess estrogenic activity. The typical assay uses a female rat or mouse with low levels of endogenous estrogens (e.g., ovariectomized adults or immature animals). In most protocols, the animals are dosed daily for 3 or 4 days. Twenty four hours after the last treatment, the animals are killed, and the uteri are removed and weighed. Increases in uterine weight compared to vehicle-treated controls are taken as evidence of estrogenicity. Although this describes the basic assay, there have been many variations on the theme that are discussed below. Historically, Bulbring and Burn (1935) employed ovariectomized immature rats; Dorfman et al. (1936) , Lauson et al. (1939) , and Dorfman and Dorfman (1954) used intact immature rats; Evans et al. (1941) , Rubin et al. (1951) , and Dorfman and Kind (1966) used intact immature mice; and Edgren et al. (1966; 1967) and Jones and Edgren (1973) employed ovariectomized pubertal and adult rats and immature mice to conduct the uterotrophic bioassay.
Most assays utilized a 3-or 4-day administration period of an estrogen to stimulate true uterine tissue growth and to help minimize the effects of temporal differences in absorption of test compounds. In such assays, however, short-acting estrogens such as E 3 and DMS will not produce dose-response curves similar to those of long-acting estrogens such as E,, E 2 , and DES (Clark and Mani, 1994) . However, if E 3 is administered at more frequent intervals or given as a sc implant, full uterine growth is stimulated (Clark and Mani, 1994) . Normal uterine growth in the rat is independent of the ovaries and adrenals prior to Postnatal Day (PND) 10, partially dependent during PND 10-15, and completely dependent during PND 16-26 (Branham and Sheehan, 1995) . In addition, a uterotrophic response to E 2 occurs concurrently with, but independently of, the endogenous estrogen surge normally seen at PND 9-11 (Branham and Sheehan, 1995) . Further, administration of DES or ethinyl estradiol (EE) during PND 10-14 induces luminal epithelial hypertrophy and increases uterine weight (Branham et ai, 1988) . Interestingly, triphenylethylene anti-estrogens such as tamoxifen, monohydroxytamoxifen, and clomiphene citrate stimulates both luminal and glandular epithelial hypertrophy (Branham etal, 1993) .
Given the large number of papers using the uterotrophic assay, a representative example of the assay conducted in the laboratory of one of the authors (J.R.R.) can best be used to describe this method in detail. The assay design given here allows one to determine whether a test compound has uterotrophic activity and, if so, to define the dose-response relationship and potency relative to a standard estrogen. With regard to reference standards, 17a-ethinyl estradiol (EE) is generally used as the standard for oral activity and E 2 for sc activity (Jones and Edgren, 1973; Edgren, 1994) .
Our typical bioassay consists of 7 treatment groups with 10 immature female rats per group. The treatment groups include (1) control vehicle; (2) three dose levels of a standard estrogen; and (3) three dose levels of a test compound. A vehicle consisting of 10% ethanol in sesame oil has been found satisfactory for the standard estrogen and the lipophilic test compounds. Eighty 13-day-old CD female rats and eight foster dams (10 pups/dam) are purchased from Charles River Laboratories (Kingston, NY). At PND 13 mean pup body weights range from 26 to 28 g for 10 replicate bioassays. At PND 19 the pups are weaned, weighed, stratified into body weight classes, and then allocated to treatment groups.
At PND 19 mean pup body weights range from 40 to 44 g. Pups outside a 35-to 50-g body wt range at PND 19 are not utilized in the bioassay. (Pups smaller than 35 g may not respond as well to estrogen as pups larger than 35 g, whereas pups larger than 50 g begin secreting endogenous E 2 by Day 3 of the assay when they reach or exceed a body weight of 60 g). Extra pups, including any out of the specified weight range, are excluded from the assay. The immature females are treated once per day on Days 19, 20, and 21. On PND 22 the rats are weighed and euthanized by carbon dioxide asphyxiation. The uteri are excised above the cervix, blotted to remove luminal fluid, and weighed to the nearest 0.1 mg. At PND 22 mean body weights range from 49 to 57 g and mean wet uterine weights range from 18 to 25 mg for the vehicle control group. Depending on the dose and potency of the compound administered uterine weights may increase to a maximum of 110 mg in this 72-hr bioassay. Utilizing an NIH log-linear regression analysis program (Prophet User's/Statistical Manual, 1990) the log dose-response data for the standard estrogen and the test compound are fitted to straight lines and the equations describing each straight line are derived. Before determining the relative potency ratio, statistical tests for significant regression, linearity, and parallelism are performed (Prophet User's/Statistical Manual, 1990) . If these conditions are met, a relative potency ratio with a 95% confidence interval is calculated (Finney, 1978) . Even if linearity and/or parallelism are not met, a range of potency ratios can be estimated using the minimum and maximum values that are common to the estrogen standard and test compound regression lines.
Representative relative potencies obtained in the oral and sc uterotrophic bioassay using these methods are presented in Tables 1 and 2 . Significantly, the synthetic estrogens, EE and DES, exhibited potent estrogenic activity whether administered po or sc. In addition, E 2 and E, share similar, but lower, potencies when given orally, whereas E, is substantially less potent than E 2 when the sc route is used. The short-acting estrogen, E 3 , has a shallow dose-response curve and is of weak potency relative to the other reference Although the uterotrophic response in the rat and mouse is commonly accepted as a sensitive measure of estrogenic activity, it suffers from a lack of specificity. For example, relatively high doses of progesterone, testosterone, and various synthetic progestagens stimulate uterine weight increases (Jones and Edgren, 1973) . Although less sensitive than the uterotrophic response, the vaginal comification response is a considerably more specific endpoint for assessing estrogenic activity (Jones and Edgren, 1973) . Based on their continued use for 50 to 75 years, the uterotrophic and vaginal comification bioassays appear to be accepted standards for assessing estrogenic activity. As such, newer bioassays (as will be discussed below) generally weigh their results against one or both of these classical bioassays.
Uterine glycogen deposition. Among the earliest and most pronounced responses of the immature rat uterus to estrogen are increased uptake, phosphorylation and utilization of glucose, and enhanced glycogen synthesis (Bitman etai, 1965; Smith etal, 1961 Smith etal, , 1968 Smith etal, , 1971 . Glycogen accumulation is significantly increased by 6 hr, reaches a maximum between 12 and 24 hr, and declines to near control levels by 48 hr (Galand et al., 1987) . Bitman and Cecil (1970) used the 18-hr glycogen deposition response in the immature rat uterus to evaluate the estrogenic activity of a number series of diphenylmethane, diphenylethane, and triphenylmethane compounds. Polychlorinated biphenyls and polychlorinated triphenyls were weakly estrogenic. Phenolphthalol and phenolphthalein, which contain /?,/?'-dihydroxy structures, also showed activity. Galand et al. (1987) confirmed that o,p'-DDT and p,p'-DDT at 12.5 mg/rat, ip, were active in the glycogen deposition assay with o,p'-DDT being the more potent of the two. Further, the glycogen deposition response to a 12.5-mg dose of o,p'-DDT was quantitatively similar to that observed with a 0.05-fig dose of E 2 . Hence, o,p'-DDT was about 4 X 10~6 times as potent as E 2 in the glycogen deposition assay.
Uterine estrogen withdrawal bleeding. In women and nonhuman primates, removal of both ovaries is usually followed a few days later by a brief period of bleeding from the uterus. Experiments have shown that sudden deprivation or diminution of either estrogen or progestin leads to uterine bleeding (Burrows, 1949; Emmens and Martin, 1964) . This is typically referred to as estrogen withdrawal bleeding. It also is known that menstruation, which occurs only in primates, can be prevented by the continual administration in sufficient quantity of either estrogen or progestin (Burrows, 1949) . These observations have led to the development of an estrogen bioassay in primates with the ovariectomized rhesus monkey being the most frequently used species (Burrows, 1949) . Estrogen administration over several days stimulates the uterine endometrium to proliferate. When estrogen treatment is discontinued (withdrawn) the uterine endometrium begins to slough after a few days. This sloughing of the endometrium resembles menses which occurs during the normal menstrual cycle of primate species (Burrows, 1949) . The time to appearance of withdrawal bleeding (latency) and duration of bleeding are the endpoints in this assay. Eckstein et al. (1952) estimated the minimal amounts of 11 estrogens required to induce uterine withdrawal bleeding when administered as a single intramuscular (im) injection in 25 ovariectomized rhesus monkeys. Vaginal lavages were performed daily to detect the onset and duration of uterine bleeding. The latency to onset of withdrawal bleeding and the duration of bleeding in days at the threshold dose were used as the endpoints. The threshold doses then were used to estimate relative potencies. Esterification of estrogens increased potency (smaller threshold dose) and duration of bleeding, but diminished the latent interval between im injection and the onset of withdrawal bleeding. Eckstein et al. (1952) concluded that the more "potent" the estrogen, the shorter the latency period and the longer the duration of bleeding. It should be noted that one drawback to this test is that the assay could be confounded by compounds with unusual pharmacokinetics, such as extremely long half-lives. Schane et al. (1972) have defined the dose-response relationship for sc-injected E 2 on withdrawal bleeding in primates. These investigations evaluated the uniformity of estrogen withdrawal bleeding and determined the relative potency of several orally active estrogens in ovariectomized rhesus monkeys. In addition, the color of the perianal sex skin was rated subjectively as a measure of estrogenic activity. Following sc E2 treatment (10 /ig/monkey/day X 10 days) of 18 ovariectomized monkeys, bleeding began an average of 9.1 days after the last E 2 injection. In addition, all monkeys had normal withdrawal bleeding at lower daily doses of E 2 (4, 6, or 8 fig E2/monkey X 10 days). The doseresponse relationship for several orally active estrogens also was established, including identification of the oral dose resulting in withdrawal bleeding in all 4 monkeys tested and no-effect levels. EE, mestranol, and E, produced withdrawal bleeding in four of four monkeys at 100 fig/day fig. Further , EE, E,, Premarin, and DES did not stimulate color development of the perianal sexual skin at daily doses below those required to produce withdrawal bleeding. In contrast, mestranol produced a change in color of the sexual skin at a daily dose below that which caused withdrawal bleeding. Taken together, the data indicated that EE, mestranol, E,, and Premarin were approximately equipotent, whereas DES was of lesser potency in the withdrawal bleeding assay. Hisaw et al. (1971) evaluated quinestrol in the rhesus monkey withdrawal bleeding assay. Quinestrol, the 3-cyclopentyl ether of EE, has prolonged estrogenic activity by virtue of its storage in, and subsequent release from, body fat. Treatment for 20 days with 10 fig E 2 /day, sc, or quinestrol (10 fig/day , sc, or 5 or 10 fig/day, po) resulted in an average latency period of 7 to 8 days for E 2 versus a latency period averaging about 12 days for quinestrol. In a second experiment, E 2 and quinestrol were given as a single dose. A single dose of 50 or 200 fig E 2 , sc, failed to produce withdrawal bleeding, whereas a single dose of 50, 100, or 200 fig quinestrol, po, produced a delay in withdrawal bleeding averaging 22 days, with no indication of a dose-response relationship in 7 of 8 monkeys. Therefore, estrogens stored in the body fat may give a different withdrawal bleeding pattern than those not stored in the fat. The latency of the response appeared to increase with decreased bioavailability at the target organ.
Generally, the estrogen withdrawal bleeding bioassay has been used to confirm rodent bioassay data and to establish estrogenic activity and potency in primates. The assay has the advantage that data can be obtained in a primate species and that animals can be dosed orally or parenterally and can be used repeatedly. It has the disadvantage that nonhuman primates are difficult to handle and costly to maintain. In addition, the uterine withdrawal bleeding endpoint is not specific for estrogens because progestins also can induce this response (Krohn, 1956) .
Uterine cell DNA and progesterone receptor synthesis and specific protein secretion in vitro. Kasis et al. (1984) have demonstrated that dispersed uterine cells from immature rats can be grown in primary monolayer culture. These dispersed cells in culture were fibroblastic in nature and thought to be myometrial cells; the cells contained estrogen receptors and were estrogen responsive. Two estrogen responses were characterized: (1) induction of progesterone receptors and (2) induction of a 130-kDa secreted protein.
No difference in DNA content was noted between control and Entreated cell cultures, so estradiol treatment did not induce cell proliferation. [ 3 H]Progesterone binding (increased number of receptors) was increased in a dose-dependent fashion by E 2 present from Days 4 through 7 of culture. The response was maximal at 10~9 M and half-maximal at 5 X 10"" M E 2 . In addition, the response was E 2 -specific in that testosterone (10~9 M) and dexamethasone (10~7 M) were without effect. In a time course experiment in which cells were treated with 10~9 M E^ from Days 7 through 10 and [ 3 H]progesterone binding assayed on Days 8, 9, and 10 of culture, progesterone receptor was induced within 1 day and the response was maximal (threefold) after 2 days of exposure. Using the same rat uterine cell system, Jordan et al. (1985) demonstrated that both Et and E 3 also induced progesterone receptor synthesis in a dose-related fashion, with Ei being about 50% and E 3 about 5% as potent as E 2 . These workers (Jordan et al., 1985) further noted that 4-hydroxytamoxifen blocked E 2 -induced progesterone receptor synthesis.
To assess whether any other uterine proteins were being affected by estrogen treatment, these uterine cells were incubated with E 2 for 1 to 6 days and then labeled with [
35 S]-methionine. Cellular and secreted proteins were evaluated by one-dimensional gel electrophoresis. Although estrogen produced no changes in cellular proteins, several secreted proteins were altered. The most striking alteration was an increase in the amount of a 130-kDa secreted protein. This increase occurred within 1 day of E 2 exposure and remained elevated over the 6 days of treatment. Induction of the secreted protein by E 2 was dose-dependent with the maximal response (2.5-fold) occurring at 10~'° M. Curiously, testosterone (10~9 M) was capable of inducing the secreted protein, but dexamethasone (10~9 M) was not (Kasis et al., 1984) .
In other related in vitro studies, Tiemann and Tuchscherer (1995) investigated the effect of various concentrations of certain organochlorine pesticides on DNA synthesis in cultured bovine uterine cells. Primary cultures of uterine epithelial, stromal, and muscle cells were cultivated to 50% confluency, and then the medium was changed to phenol red and serum-free RPMI 1640 without or with 0.1, 1, 10, 100, 725, 1450, 2900, and 5800 ng pesticide/100 ml incubation volume. After 24 hr, [ 3 H]thymidine was added. The cells were harvested 12 hr later and incorporation of radioactivity into DNA was determined. At concentrations of 100 ng/ 100 ml or less DDT and hexachlorocyclohexane (\HCH) significantly stimulated DNA synthesis in uterine epithelial cells, and methoxychlor (MXC) elevated DNA synthesis in uterine stromal cells relative to the untreated control cells. Conversely, there was a dose-dependent decrease in DNA synthesis in uterine epithelial, stromal, and muscle cells over the concentration range of 725 to 5800 ng/100 ml medium for these three organochlorine pesticides, perhaps reflecting cytotoxicity. In contrast, it is noteworthy that Kasis et al. (1984) saw no changes in DNA content or cell proliferation in E 2 -treated primary monolayer cultures of uterine cells from immature rats. Therefore, the effects of DDT and X.HCH on DNA synthesis in bovine uterine cells may not represent estrogenic responses (Tieman and Tuchsherer, 1995) . To date, the rat and bovine uterine cell systems have not been adopted widely by other investigators in screening for estrogenicity.
Non-Reproductive-Tract Target Tissue
Pituitary cell prolactin synthesis in vitro. Lieberman et al. (1978) have shown that primary cultures of dispersed rat pituitary cells from immature female rats respond in a dosedependent manner to E 2 by increased incorporation of radiolabeled leucine into prolactin, but not other cellular proteins. At a concentration of 10~9 M, E^, DES, and E, stimulated a three-to fourfold increase in prolactin synthesis, whereas testosterone, 5 a-dihydrotestosterone (5aDHT), progesterone, and corticosterone at 1CT 9 M were without effect. Testosterone at 10~7 M, however, had a slight stimulatory effect on prolactin synthesis, but 5aDHT was not tested at 1(T 7 M. Jordan et al. (1985) found that E, and E 3 were approximately 50% as potent as E 2 with respect to induction of prolactin synthesis in cultured rat pituitary cells. In addition, nonsteroidal estrogen antagonists antagonized E 2 -induced prolactin synthesis in dispersed rat pituitary cells in primary culture (Lieberman et al., 1983a,b) .
MCF-7 cell proliferation in vitro (Soto et al., "E-screen assay'').
The MCF-7 cell line was originally derived from a hormone-dependent human metastatic breast cancer . Shortly thereafter, Brooks etal. (1973) demonstrated that these cells contained estrogen receptors (ER), and Lippman et al. (1976 Lippman et al. ( , 1977 showed a variety of cellular growth responses to estrogens and inhibition of cellular proliferation by the anti-estrogens, tamoxifen and CI-628. A number of specific cellular products also have been found to be under estrogenic control in MCF-7 cells, including thymidine kinase, progesterone receptor, lactic dehydrogenase isoenzymes, plasminogen activator, and cytoplasmic and secreted proteins of unknown function (cited in Lippman, 1981) . Kendra and Katzenellenbogen (1987) further noted that estrogen increased ornithine decarboxylase activity, which appeared to be required for estrogen-stimulated cell proliferation. Human MCF-7 cells (C 7 MCF7-173 clone) grew as estrogen-dependent tumors in nude mice, but they were not estrogen-dependent for proliferation in serumless culture media. Charcoal-dextran-stripped female human serum or fetal bovine serum supplemented media inhibited cellular proliferation in a dose-dependent manner, and estrogens reversed this inhibition. These results are consistent with the interpretation that human and bovine sera contained an inhibitor of MCF-7 cell proliferation and that estrogens promoted proliferation by neutralizing this serum inhibitory factor Sonnenschein, 1984, 1985) . Subsequently, Soto and colleagues (1991 Soto and colleagues ( , 1992 Soto and colleagues ( , 1994 have utilized MCF-7 cells in a serum-containing culture system to assess the estrogenic activity of a number of xenobiotics. The standard assay employed charcoal-dextran-stripped female human serum and a 6-day culture period. Proliferation was determined by lysing the MCF-7 cells and counting cell nuclei using a Coulter counter. The estrogenic activity of test compounds was assessed by (1) determining their relative proliferative potency (RPP) (the ratio between the minimal concentration of E 2 needed for maximal cell yield at 6 days and the minimal dose of the test compound to achieve similar effect) and (2) measuring their relative proliferative effect (RPE) (100X the ratio between the highest cell yield obtained with the test chemical and that with E 2 ). The RPE indicates whether the test compound induces (1) a proliferative response quantitatively similar to the one obtained with E 2 , that is, a full agonist (RPE = 100) or (2) a proliferative yield significantly lower than the one obtained with E 2 , that is, a partial agonist. Soto et al. (1994) proposed that the MCF-7 cell proliferation assay may be useful to estimate ' 'the estrogenic burden due to environmental contaminants" and one could use the "Escreen test to screen chemicals for their estrogenicity before they are released into the environment." Specific alkylphenols, pesticides, polychlorobiphenyls, phytoestrogens, and phytohormones were among the chemicals found to yield positive results in this in vitro cell proliferation assay. It should be noted, however, that some of these findings have not as yet been confirmed in the in vivo tissue response assays, such as the uterotrophic or vaginotrophic assays.
Recently, other workers (Desaulniers et al., 1995) have attempted to further refine the MCF-7 assay using cloned and wild-type MCF-7 cells. Five parameters for assessing proliferation were used: (1) metabolic reduction of soluble dimethylthiazolyldiphenyltetrazolium bromide (MMT assay); (2) reduction of Alamar Blue (AB); (3) incorporation of [ 3 H]thymidine ( 3 H-TI); (4) DNA assay; and (5) counting cell nuclei. In addition, to investigate the possibility that cell proliferation was responding to conditions other than an estrogenic stimulus, the effects of different culture conditions on the proliferation of MCF-7 cells were investigated. Some internal inconsistencies are shown in the data. Significant increases in [ 3 H]thymidine incorporation were detected at 10~1
3 M E 2 in wild-type MCF-7 cells grown in medium supplemented with 15% human serum. Conversely, low concentrations of E 2 (10~1 4 to 10" 12 M) inhibited cell proliferation compared to controls in 11 of 22 of the MCF-7 cell proliferation assays, whereas maximal proliferation was consistently induced at 10~" M E 2 . Therefore, increases in [ 3 H]-thymidine incorporation at 10~1 3 M E 2 did not appear to accurately reflect increases in cell proliferation in this system. Welshons et al. (1990) also have recently utilized the in vitro MCF-7 assay system to detect dietary estrogens in animal feeds. Dose responses for natural and synthetic estrogens were used to determine the concentration that produced a half-maximal growth response. E2 was 117 times more potent than zearalenone, and only 0.54 pg E 2 /ml medium was required for half-maximal response. The synthetic estrogens, DES, dienestrol, and hexestrol were about equipotent to E2. Coumestrol, found in clover and alfalfa, was the most potent of the phytoestrogens tested, but was only 13% as potent as zearalenone. Myco-and phytoestrogens also have been shown to induce a 52-kDa secreted protein in MCF-7 cells (Mayr et al, 1992) . Potential dietary exposure was also considered when Brotons et al. (1995) used the MCF-7 cell assay as a measure of estrogenic potency of bisphenol A, which may be leached from food cans.
This cell-based system revealed some "cross-effects": Jeng et al. (1991 Jeng et al. ( , 1992 Jeng et al. ( , 1993 have shown that the antiprogestin, RU 486, and certain 19-nortestosterone derivatives that are progestational components of oral contraceptives are estrogenic in the MCF-7 cell culture system at high concentrations (10~6M). These steroidal compounds appear to be active in this system by virtue of their ability to weakly bind to the estrogen receptor. In an earlier study, RU 486 (10~7 to 10" 6 M) also stimulated the growth of the human breast cancer cell line T 47D in a dose-related manner (Bowden et al., 1989) .
Estrogen Receptor Binding
Jensen and Jacobson (1960) made the crucial discovery that following administration to female rats in vivo [ 3 H]-labeled estrogens were specifically retained only within tissues known to be responsive to these hormones and were rapidly cleared from other tissues. Subsequent studies in a number of laboratories revealed that the retention mechanism was related to the presence within target tissues of proteins with high binding affinity and specificity for estrogens. Estrogen interaction with these receptor proteins is the primary event in hormone action (Clark and Mani, 1994) .
It follows that potential estrogenic activity can be inferred for a compound by its ability to compete with [ 3 H]E 2 for binding to target tissue receptors. Although the ability of a compound to inhibit [ 3 H]E2 binding to estrogen receptors in vitro suggests a potential mechanism of action, it cannot predict whether the compound will be an agonist or an antagonist. This information must be used in combination with an evaluation of estrogenic properties in vivo (Jordan et al., 1985) . In addition, a compound metabolized to an estrogen in vivo may not be detected by an in vitro system lacking the appropriate metabolic systems. Hence, one cannot rely solely on estrogen receptor binding assays to establish the estrogenic activity of a compound.
Generally, estrogen receptor binding assays are conducted to establish the binding affinity of a compound for the estrogen receptor relative to E 2 . In principle, any estrogen target tissue can be used as the source of the estrogen receptor. In practice, the rodent uterus is the target organ most often used because of its relevance, size, accessibility, and high concentration of estrogen receptors (Clark and Mani, 1994) . Jobling et al. (1995) also tested 20 chemicals for binding to the fish liver estrogen receptor to determine whether the chemicals competed with E 2 for receptor binding. Some inhibition was seen at high concentrations, but they were not tested for a biological response in fish. Selected chemicals were also tested in breast cancer cell lines for cell proliferative activity and in a reporter gene system to determine transcriptional activity. However, the full range of compounds was not tested in all three assays, so no judgment can be made about concordance of the test system responses.
More recently, transformed yeast cells (McDonnell et al., 1991; Zysk et al., 1995) or transfected insect cells using a baculovirus expression system (Obourn et al., 1993; Patterson et al., 1995) have been utilized to produce milligram quantities of human estrogen receptor. Extracts of these transfected cells provide a ready source of estrogen receptor for research and testing purposes.
In a typical competitive hormone binding assay (e.g., Ireland et al., 1980) , a high-speed centrifugal fraction of uterine cytosol or cell extract is prepared as the source of the estrogen receptor. Aliquots of the uterine cytosol or cell extract are incubated with 2 X 10~9 M (Ireland et al, 1980) . Competitive binding curves are generated by plotting the percentage specifically bound [ 3 H]E 2 (Y axis) against the logio concentration of the unlabeled competitor (Xaxis). The RBA for E2 is arbitrarily defined as 100%. Competitors with RBAs above 100% have greater binding affinity and those below 100% have lesser binding affinity than E 2 (Reel et al, 1979) .
Recently, Nagel et al. (1995a,b) pointed out that current in vitro estrogen receptor binding assays do not address the question of how serum binding proteins influence the biological activity of estrogens. These workers developed a relative binding affinity-serum modified access (RBA-SMA) assay to determine the effect of serum on the access of various estrogens to estrogen receptors within intact MCF-7 human breast cells.
Serum modified access (SMA) was calculated by dividing the RBA measured in 100% adult human male serum (noncharcoal stripped) by the RBA measured in serum-free medium. An SMA > 1 indicated that the biological impact of a compound relative to E 2 would be underestimated in serum-free assays, while an SMA <1 indicated protection in serum and thus a decrease in relative access. DES, known not to be bound by serum proteins (unlike E 2 ), showed enhanced access in serum (SMA = 4.5). The phytoestrogens coumestrol, genistein, and equol showed substantial enhanced access in serum (SMA = 12.6, 10.5, and 11.8, respectively). Of the alkylphenols, including bisphenol A, octylphenol showed the greatest estrogenic activity in the MCF-7 cell proliferation bioassay. However, the compound showed a 38-fold decrease in access when in 100% serum (SMA = 0.026), giving it the lowest RBA. Nonylphenol also showed a decrease in relative access in serum (SMA = 0.20). In contrast, bisphenol A, a component of polycarbonate, had a lower RBA in serum-free medium (0.006%) than octylphenol, but showed a higher RBA in serum (0.01%) and thus a slightly enhanced access to estrogen receptors (SMA = 1.7). These results indicated that the impact of environmental estrogens may be substantially affected by their specific access to cells from serum and that environmental estrogens must be considered on an individual basis.
Estrogen Receptor-Dependent Transcriptional Expression
The estrogen receptor (ER) functions by modulating the rate of transcription of its target cell genes. The estrogen receptor contains at least two regions that are able to stimulate transcription and these are called transcriptional activation functions (TAFs). TAF-1 is located N-terminal to the DNA binding domain, while TAF-2, located in the C-terminal hormone binding domain, is dependent upon estrogen binding for its activity. The relative activities of TAF-1 and TAF-2 vary depending upon the responsive promotor and target cell context (Danielian et at, 1993; Tzukerman et ai, 1994) .
Currently, it is known that several components are required to elicit an estrogenic response. These include the ER, an active estrogen ligand such as E 2 , an ER DNA binding site (ERE; also known as the estrogen response element), and other accessory proteins. With the emergence of recombinant DNA technology, bioassays based on the ability of a compound to stimulate estrogen receptor-dependent transcriptional activity have come into being. These gene expression assays utilize mammalian cell lines and/or yeast strains in which an acute estrogen response is created by cotransfecting cultured cells with plasmids containing recombinant estrogen receptor cDNA and an ERE-containing promoter-reporter cDNA. Mammalian cells also are transfected with an internal control cDNA that will distinguish differences in the level of transcription from differences in the efficiency of transfection or in the preparation of cell extracts (Miksicek, 1993 ). An enzyme frequently used for internal control purposes is the reporter Escherichia coli /?-galactosidase (/?-Gal), which is expressed in transfected mammalian cells from a promoter with a broad host range (e.g., SV40 early promoter or the Rous sarcoma virus LTR). Several investigators have used estrogen receptor-dependent transcriptional expression systems to test for estrogenic activity as follows: Mayr et ai (1992) developed a stably transfected cell line (LeC-9) that they used to assess the estrogenic activity and cytotoxicity of zearalenone, phytoestogens, and cereal extracts. The cloned LeC-9 cells (originally derived from mouse L fibroblast cells) contain the human estrogen receptor gene, an ERE combined with the thymidine kinase (TK)-promoter-chloramphenicol acetyltransferase (CAT) reporter gene, and a /3-Gal internal control gene. In particular, the LeC-9 cells have a very low level of endogenous CAT activity that can be stimulated 200-to 300-fold by E 2 .
The cloned LeC-9 cells also constitutively express /?-Gal enzymatic activity at a level 20-fold higher than the background in nontransfected cells. Thus, /3-Gal enzymatic activity provides a convenient internal marker for monitoring the cytotoxicity of a given test compound in this transcriptional expression assay. Induction of CAT synthesis in cloned LeC-9 cells with a series of known estrogenic compounds produces a family of sigmoid dose-response curves. E 2 gave a dose-dependent increase in CAT activity over the concentration range of 10"'° to 10~8 M, zearalenone from 8 X 10~9 to 2 X 10~7 M, coumestrol from 3 X 10~7 to 4 X 10" 6 M, genistein from 8 X 10~7 to 1 X 10~5 M, and daidzein from 6 X 10~6 to 5 X 10" 5 M. Significantly, the phytoestrogens (coumestrol, genistein, and daidzein) exhibited cytotoxicity, as indicated by decreased /?-Gal activity at concentrations ranging from 2 X 10~6 to 5 X 10~5 M, depending upon the specific phytoestrogen. Miksicek (1993) investigated the estrogenic activity of a series of plant flavonoids using HeLa cells transfected with the human estrogen receptor expression plasmid pER-18 and the estrogen-responsive reporter plasmid pERE-TK-CAT. Using this assay system, a variety of naturally occurring flavonoid pigments were found to possess previously unrecognized estrogenic activity.
Other xenobiotics also have been found to be estrogenic in transcriptional expression systems. White et ai (1994) evaluated the estrogenic activity of a series of alkylphenolic compounds using transcriptional activation assays. For this work, MCF-7 or chicken embryo fibroblasts (CEFs) were transfected with the reporter plasmid pEREBLCAT and the internal control plasmid, pJ3 luciferase. In addition, the CEF cells also were transfected with a mouse estrogen receptor expression vector, because unlike MCF-7 cells, they contain no endogenous estrogen receptor. In the transfected MCF-7 cells, 4-octylphenol (OP) stimulated transcription of the reporter gene EREBLCAT approximately threefold at a concentration of 10~7 M and five-to sevenfold at 1(T 6 to 10~5 M, an increase similar to that obtained in the presence of 1CT 8 M E 2 . 4-Nonylphenoxycarboxylic acid (NP1EC) and, to a slightly lesser extent, 4-nonyl phenol (NP) and 4-nonyl phenoldiethoxylate (NP2E0) also stimulated transcription at concentrations in the range of 10~6 to 10~5 M. Similar results were obtained in CEF cells cotransfected with the EREBLCAT reporter gene and the mouse estrogen receptor cDNA. In CEF cells not transfected with the mouse estrogen receptor cDNA, no stimulation of the EREBLCAT reporter gene was observed. The observation that the transcriptional stimulation was dependent on the presence of a cotransfected receptor confirms that the action of the alkylphenolic compounds was mediated by the estrogen receptor. In addition, the estrogen antagonists, 4-hydroxytamoxifen (1(T 7 M) and ICI 182,780 (1(T 7 M), inhibited the agonist activity of E 2 (10~8 M) and OP (10~6 M) in the MCF-7 transcriptional assay system, again indicating that these effects were mediated by the estrogen receptor. Zacharewski et al. (1995) used MCF-7 cells transiently transfected with a Gal4-estrogen receptor chimeric construct (Gal4-HEGO) and a Gal4-regulated luciferase reporter gene (17m5-G-Luc) to demonstrate that paper mill black liquor contains estrogenic components. The estrogen receptor-mediated induction by the black liquor was antagonized by the pure anti-estrogen, ICI 164,384. In addition, the black liquor inhibited E 2 induction of the reporter gene, suggesting that it contained anti-estrogenic properties as well. Bondy and Zacharewski (1993) also have demonstrated that dextran-coated charcoal treatment of fetal calf serum is only marginally effective in depleting serum of estrogens. These workers suggest the use of ICI 164,384 as a control to investigate estrogen-responsive genes in order to obtain a more accurate and reproducible basal level of activity. Using ICI 164,384 as a baseline control, it was found that some promoters were more sensitive to media conditions than others. Thus, medium preparation and conditions can affect the responsiveness of a reporter gene. For example, poor induction of a reporter gene may be attributable to (1) media-borne estrogens that have already induced the response and/or (2) reduced serum concentrations in the media that compromise the response while having negligible effects on cell viability (Bondy and Zacharewski, 1993) .
Finally, Saccharomyces cerevisiae transformed with the human estrogen receptor gene and estrogen response elements linked to a reporter structural gene for /J-galactosidase White et al. (1994) have been used to detect estrogens (Klein et al., 1994 (Klein et al., , 1995 and to investigate the pharmacology of estrogen agonists and antagonists (Zysk et al., 1995) . During the past 10 to 20 years a number of new in vitro biological assays have been developed, as described above. Only two of these test systems have been used to any significant extent for estrogen testing. These are the MCF-7 cell proliferation assay and various transcriptional activity assay systems. The uncertainty regarding the mechanism of action of estrogens and their estrogenic specificity in the MCF-7 cell proliferation assay render it somewhat less desirable than the transcriptional expression assays which rely on a well-defined estrogen receptor-dependent mechanism.
The MCF-7 breast cancer cell proliferation assay has been proposed as a general screen for estrogenicity for environmental samples (Soto et al., 1993) . Although the simplicity of such a system is attractive, even the best in vitro assay or battery of such assays is unlikely to be sufficient, unless one is testing a series of related chemicals that has been characterized in vivo and has a specific and common mecha- nism of action that is appropriate to the test system. Many factors can affect the biological potency expressed in a biological assay. For example, serum had profound effects on the biological activity of alkylphenols in MCF-7 cells (Nagel etal., 1995a,b) .
TESTING STRATEGY
The mammalian estrogen biological assays are summarized in Table 3 . Selected assays (vaginal cornification, uterotrophic response, estrogen receptor binding, and estrogen receptor-dependent transcriptional expression) from the Table 3 list are recommended for testing of xenobiotics and complex environmental mixtures. The pros and cons of the selected assays are detailed in Table 4 . Depending on what is known about a chemical from other studies, one may choose any of the recommended biological assays or alternative assays to further assess the potential estrogenicity of that chemical. A tiered system is described below, but it is only an example of how one could assess estrogenicity. Selection of an appropriate assay cannot be automatic through a predesigned, "one size fits all" scheme. Selection will be tailor-based on known information including toxicity, exposure, chemical characteristics, production, environmental release, and persistence.
One potential series of tests is illustrated in Fig. 1 . Test compounds or mixtures should be screened initially for binding to the estrogen receptor. If binding is observed, testing could next be conducted in an estrogen receptor-dependent transcriptional expression system. Compounds or mixtures that do not bind to estrogen receptors are unlikely to possess direct estrogenic activity. Nonetheless, this can be verified in the transcriptional expression system, if desired. Compounds or mixtures that bind to the estrogen receptor, but that do not activate transcription, may well be estrogen antagonists. Hence, these could be tested in combination with E 2 in the transcriptional expression assay in order to detect antagonist activity. Compounds or mixtures that exhibit both estrogen receptor binding and estrogen receptor-dependent transcriptional activation then should be tested in vivo by various routes in the classical uterotrophic and vaginal cornification bioassays to confirm estrogenic activity and to establish relative potency versus the reference standards, E 2 , EE, or DES. Similarly, putative antagonists also can be tested in vivo in combination with E 2 to confirm antagonist activity.
One major drawback to in vitro tests is that pro-estrogens would not be detected in the initial in vitro assays and, consequently, would not be given a high priority for subsequent in vivo testing. If chemical structural considerations lead one to suspect at the outset that the candidate may well be a pro-estrogen, estrogen, or anti-estrogen, then it should be tested directly in the vaginal cornification and/or uterotrophic bioassay. In this instance, the in vitro assays would be used to confirm and provide additional information concerning the mode of action. Xenobiotics suspected of being proestrogens must be tested directly in the in vivo bioassays.
RBA in the receptor binding assay also frequently provides some indication of expected relative estrogenic or antiestrogenic activity in the transcriptional expression assay and in vivo bioassays. Receptor binding activity is one requi- 
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Unlikely to be estrogenic in vivo   FIG. 1 . Possible test array for potentially estrogenic/anti-estrogenic compounds or mixtures. This test array does not imply that all tests need to be conducted in every instance or in this particular sequence. "Lack of direct estrogenic activity may be confirmed if desired using the estrogen receptordependent transcriptional activity assay.
b Relative potency versus reference standards (E 2 , EE, or DES) should be determined in these assays. c If the compound is positive for receptor binding activity, but negative for E-receptor-dependent transcriptional activity, it is a potential estrogen antagonist. The compound or mixture should be tested in combination with E 2 to detect antiestrogenic activity. ''Suspected pro-estrogens should be tested directly in the in vivo biological assays. If the compound or mixture is active in all four biological assays it is estrogenic. site step in causing an effect, but the ability of any agent to modulate the endocrine system in a living organism is limited by its ability to reach its receptor in both sufficient concentration and in an active form in vivo, where in vivo concentrations are sufficient to compete effectively with endogenous ligand. Therefore, RBA is not always a good quantitative predictor for these bioassays. Xenobiotics found to be the identified metabolite or suspected proximate estrogen should then be tested for estrogen receptor binding and receptor-dependent transcriptional activation to directly confirm their estrogenic nature.
The presence of an environmental agent and the identification of potential activity in an in vitro assay are not sufficient to determine that there is a risk of endocrine or reproductive effects. As with other toxicants, the target dose determines toxicity. The toxicant must be transported to the target organ at sufficient concentrations to reach a critical dose. The ultimate toxic or pharmacologic response depends on a sufficient dose and target tissue response to cause a biological effect (Lamb, 1989) . This paper reviews various tests for assessing estrogenic activity. A potential strategy is also outlined. However, in risk assessment, one may be concerned about more general effects on reproduction, development, and target organ toxicity. We do not propose that a battery of estrogen assays is necessarily sufficient or even required for safety assessment. A chemical may bind to the estrogen receptor and cause biological responses that are typical of an estrogen, but the response may not be toxicologically significant because of the dose required to produce an effect, differences in metabolism, or the existence of other more sensitive endpoints of toxicity which would be more relevant for risk assessment. In fact, the compound may be estrogenic but not potent enough to cause adverse effects on the reproductive system. More broadly based toxicity tests, for safety assessment, should include endpoints that would be sensitive to agents that cause adverse effects through an estrogenic mode of action. However, as with other toxicants, the mechanism of action may not be clear without further testing. The proposed scheme is one way to test specifically for an estrogenic mode of action.
DISCUSSION AND CONCLUSIONS
In the foreseeable future, it appears that combinations of estrogen receptor binding activity and transcriptional and various cellular assays may be used as initial screening methods to detect direct estrogenic and anti-estrogenic activity. In addition, the in vivo uterotrophic and vaginal cornification bioassays will continue to be employed as primary or secondary methods to identify or confirm estrogenic and antiestrogenic activity and relative potency and to detect proestrogens.
The relative potency of any estrogen, compared to E 2 , varies for different endpoints, even in the same target organ (Hisaw, Jr., 1959) . One cannot reliably predict the estrogenicity of any specific agent on the basis of a single test. Estrogenicity as currently understood constitutes a multiplicity of target tissue responses. Even binding assays cannot predict whether an agent will be an agonist or an antagonist; rather, the results must be considered in conjunction with estrogenic properties in vivo (Jordan el ai, 1985; Markaverich et al., 1995) . The choice of species for testing should also be dictated, as much as possible, by similarities in metabolism to humans or the target species of concern. Also, hormone levels are controlled by internal feedback loops that are avoided in many in vivo assays that remove endogenous sources of estrogens. Other types of assays, like toxicity tests, that evaluate intact systems may give conflicting results.
Assays for estrogenic activity are often designed to measure discrete responses in isolated systems. Processes such as absorption, disposition, metabolism, excretion, bioaccumulation, and repair in the intact organism can alter the toxic or pharmacologic response, thereby rendering the findings in isolated assays meaningless for risk assessment.
Such practical concerns would seem to favor whole animal bioassays over in vitro assay systems. In animal systems, liver metabolic processes, however, can serve to inactivate and eliminate endogenous steroid hormones. If these metabolic processes are disrupted or overwhelmed by toxicants, endogenous estrogen levels may increase. This increase in endogenous estrogens may lead to the illusion of direct hormonal activity because the target organ responds to the endogenous estrogens that remain in the body through an indirect effect on metabolism and excretion. Thus, complete assessment for estrogenic activity may be best evaluated through a combination of in vitro and in vivo biological assays, such as those described by Markaverich (1995) .
The scheme proposed in this paper is one way to test for estrogenicity. We do believe, however, that chemical safety assessment should be based on much more than estrogenicity. In fact, estrogenicity is not necessarily an adverse effect and frequently may not be the most appropriate effect for risk assessment. Other toxicology testing protocols exist that would identify whether a chemical has the potential to cause adverse effects on reproduction through an estrogenic mode of action or any other mode of action. This strategy has been designed for use when one specifically needs to determine whether a chemical can be acting as an estrogen. It is hoped that this will provide a useful framework and a rational alternative to the less well-defined approaches currently in use.
